 |
인쇄하기
취소
|
Boryung’s Fimasartan wins new drug development award
Boryung Pharmaceutical’s new antihypertensive agent Fimasartan received an award from the Korean Drug Research Association.
A KDRA spokesman said that Fimasartan received the prize in recognition of its long-standing research and efficacy. The award ceremony will be held today in Seoul National University.
Fimasartan is a novel, nonpeptide angiotensin II receptor antagonist with a selecti...
A KDRA spokesman said that Fimasartan received the prize in recognition of its long-standing research and efficacy. The award ceremony will be held today in Seoul National University.
Fimasartan is a novel, nonpeptide angiotensin II receptor antagonist with a selecti...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.